Peptides DB
Research-centric peptide and protocol reference hub

Adalank (N-Acetyl Selank Amidate) record · updated 17h ago

Neuro & moodMetabolic & appetiteGrade D · emergingResearch use only
Research on SelankJump to the evidenceCompare
What is Adalank (N-Acetyl Selank Amidate) used for?

Adalank (N-Acetyl Selank Amidate) is a modified analog of the Russian heptapeptide Selank, designed for enhanced metabolic stability and investigated for anxiolytic and nootropic effects.

How it works: Anxiolytic heptapeptide (Tuftsin analog)

Primarily researched for · Neuro & moodRoute · Intranasal / subcutaneous (research use)

Development stage

where Adalank (N-Acetyl Selank Amidate) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus. It describes the research record, not a recommendation.

Identity
NameAdalank (N-Acetyl Selank Amidate)
Full name—
Sequence—
ClassCognitive
Research levelEmerging
Discovered byCurated master list · 2026
Pharmacology
MechanismAnxiolytic heptapeptide (Tuftsin analog)
RouteIntranasal / subcutaneous (research use)
Half-life—
Time to peak—
Duration—
Extraction confidence0.50
Effect profile · 0–5
Neuro & mood: Healing 1.0, Muscle 0.0, Metabolic 2.0, Neuro 4.0, Sleep 1.0, Immune 1.0, Skin 0.0Healing & recovery — 1.0 / 5Metabolic & appetite — 2.0 / 5Neuro & mood — 4.0 / 5Sleep & circadian — 1.0 / 5Inflammation & immune — 1.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin1.00.02.04.01.01.00.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies0
Human / animal / cellular0 / 0 / 0
Highest trial phase—
Years covered—
Latest study—
Publication history
No publication years on file
——
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

no studies of its own · 6 from its parent compoundOpen in the library →
Evidence is for the parent compound

No study in this library has tested Adalank. Adalank is a chemically modified form of Selank, and the papers below examined Selank — each row is labelled with the compound that study actually looked at.

Adalank is not Selank. Altering a molecule — adding a group to it, or keeping only part of the chain — can change what it binds to, how much of it reaches the target, how long it lasts and what it does at a given dose. None of that was measured below. Research on Selank is not evidence that Adalank does the same thing, or that it is as safe.

Parent compoundSelank
StudyTypeYearSummary depth
Short-term nitrogen addition mediates nutrient allocation and resorption trade-offs in Populus koreana: insights for vegetation restoration on volcanic lava platform.
FindingN addition increased soil total organic carbon (TOC) by 23.04–142.68% and total nitrogen (TN) by 2.94–95.59%.
—2026Full text read0.70
Using nutrient limitation experiments to inform nutrient management thresholds in wadeable streams.
FindingAmbient total N thresholds for 50% probability of N limitation at 1.37-1.93 mg/L.
—2026Full text read0.80
Semantic Scholar search for Selank
TakeawayNot reported in abstract.
—2010Title only0.00
Effect of perioperative ONS combined with intestinal microecology in patients with colorectal cancer: a randomized clinical trial.
FindingPrealbumin (PA; 174.0 ± 38.0 g/L vs. 149.7 ± 42.9 g/L, t = -2.358, p = 0.022)
Human2025Full text read0.80
A study of the correlation between urinary perchlorate, nitrate, thiocyanate, and serum liver function indices.
FindingP-overall for non-linear relationship of perchlorate with LDH, TBIL, and TP: <0.0001.
Human2025Full text read0.80
Efficiency in packed red blood management for brain tumor resection: multicentre prospective cohort study (TScoreBTR).
Finding6.6% intraoperative transfusion prevalence (95% CI: 5.4 to 8.0%)
Human2022Full text read0.80